ING Group’s Ligand Pharmaceuticals LGND Stock Holding History

ING Group’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-4,815	Closed	-$343K	–	633
2019 Q2	$343K	Sell	4,815 -207	-4%	-$15.2K	0.01%	624
2019 Q1	$394K	Sell	5,022 -201	-4%	-$15.2K	0.01%	527
2018 Q4	$442K	Buy	+5,223	New	+$557K	0.01%	489

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ING Group's LGND Position: Q3 2019 in Review

ING Group sold out of Ligand Pharmaceuticals (LGND) in Q3 2019, closing a stake of 4,815 shares — an estimated $343K sold.

ING Group first reported a position in LGND in Q4 2018 and held it in 3 quarters. The position peaked at $442K in Q4 2018. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

ING Group reported no remaining Ligand Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
ING Group sold 4,815 Ligand Pharmaceuticals shares in Q3 2019, an estimated $343K.
ING Group first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 3 quarters.
ING Group's Ligand Pharmaceuticals position peaked at $442K in Q4 2018.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on ING Group's 13F filing for Q3 2019, filed 8 Nov 2019.